目次

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hyperphosphatemia In Chronic Kidney Disease - Overview
Hyperphosphatemia In Chronic Kidney Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hyperphosphatemia In Chronic Kidney Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hyperphosphatemia In Chronic Kidney Disease - Companies Involved in Therapeutics Development
Ardelyx Inc
China Nuokang Bio-Pharmaceutical Inc
Citragen Pharmaceuticals Inc
OPKO Health Inc
Panion & Bf Biotech Inc
Shield Therapeutics Plc
Unicycive Therapeutics Inc
Vidasym Inc
Vifor Pharma Ltd
Hyperphosphatemia In Chronic Kidney Disease - Drug Profiles
CGN-002 - Drug Profile
Product Description
Mechanism Of Action
fermagate - Drug Profile
Product Description
Mechanism Of Action
ferric citrate - Drug Profile
Product Description
Mechanism Of Action
lanthanum dioxycarbonate - Drug Profile
Product Description
Mechanism Of Action
lanthanum polystyrene sulfonate - Drug Profile
Product Description
Mechanism Of Action
PT-20 - Drug Profile
Product Description
Mechanism Of Action
Small Molecule for Hyperphosphatemia - Drug Profile
Product Description
Mechanism Of Action
succharated ferric oxide - Drug Profile
Product Description
Mechanism Of Action
tenapanor hydrochloride - Drug Profile
Product Description
Mechanism Of Action
VS-501 - Drug Profile
Product Description
Mechanism Of Action
Hyperphosphatemia In Chronic Kidney Disease - Dormant Projects
Hyperphosphatemia In Chronic Kidney Disease - Discontinued Products
Hyperphosphatemia In Chronic Kidney Disease - Product Development Milestones
Featured News & Press Releases
Nov 10, 2022: Unicycive completes enrollment of pivotal bioequivalence study for RENAZORB (lanthanum dioxycarbonate), an investigational treatment for hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis
Nov 06, 2022: Unicycive Therapeutics announces abstract on Renazorb selected for presentation at American Society of Nephrology’s Kidney Week 2022
Feb 02, 2022: Unicycive announces Renazorb pre-clinical and clinical data selected for presentation at National Kidney Foundation Spring Clinical Meeting
Nov 29, 2021: Unicycive Therapeutics receives confirmatory guidance on renazorb regulatory pathway
Dec 09, 2020: Akebiashares program: current approaches for managing hyperphosphatemia and caring for patients via telehealth
Jan 28, 2019: Velphoro doubles percentage of patients reaching target serum phosphorous levels in new study published in Journal of Renal Nutrition
Jan 06, 2017: Shield Therapeutics Provides Update on PT20
Oct 14, 2016: Keryx Biopharmaceuticals Announces Presentations of Data at the American Society of Nephrology Kidney Week 2016 Annual Meeting
Sep 24, 2015: Keryx Receives European Approval for Fexeric (ferric citrate coordination complex) for the Treatment of Hyperphosphatemia in Adults With Chronic Kidney Disease
May 07, 2015: Phosphate Therapeutics announces positive results in the PEACH pivotal study of its novel phosphate binder (PT20) for the treatment of hyperphosphataemia
Mar 04, 2015: Keryx Biopharmaceuticals Announces Publication of Auryxia (ferric citrate) Analysis in Journal of the American Society of Nephrology
Jan 09, 2015: Keryx Biopharmaceuticals Turns to Veeva Commercial Cloud to Support First FDA-Approved Product Launch
Nov 17, 2014: Keryx Biopharmaceuticals Announces Trade Name Auryxia for Ferric Citrate
Nov 15, 2014: Keryx Biopharmaceuticals Announces Results From Ferric Citrate Phase 3 Long-Term Safety Extension Study
Oct 01, 2014: Keryx Biopharmaceuticals Announces Issuance of a New U.S. Patent for Ferric Citrate Covering Orally Administrable Forms
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Ardelyx Inc, 2022
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by China Nuokang Bio-Pharmaceutical Inc, 2022
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Citragen Pharmaceuticals Inc, 2022
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by OPKO Health Inc, 2022
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Panion & Bf Biotech Inc, 2022
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Shield Therapeutics Plc, 2022
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Unicycive Therapeutics Inc, 2022
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Vidasym Inc, 2022
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Vifor Pharma Ltd, 2022
Hyperphosphatemia In Chronic Kidney Disease - Dormant Projects, 2022
Hyperphosphatemia In Chronic Kidney Disease - Discontinued Products, 2022

List of Figures
Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022